The collaboration leverages NovaBay's extensive expertise in eye care, demonstrated by its Avenova brand, and Sonoma's ability to distribute hypochlorous acid products internationally
NovaBay, Sonoma sign deal to sell Avenova-branded products in EU. (Credit: Bruno Henrique from Pixabay)
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals have reached an agreement regarding the sale and promotion of Avenova-branded products within the European Union by Sonoma.
The upcoming products will integrate Sonoma’s existing eye product, Ocudox, which has already obtained a Class IIB CE mark for European Union sales.
Bearing the Avenova brand, these joint products are anticipated to be distributed through Sonoma’s established European network.
The collaboration leverages NovaBay’s extensive expertise in eye care, demonstrated by its Avenova brand, and Sonoma’s ability to distribute hypochlorous acid products internationally.
Sonoma will manufacture Ocudox by Avenova, adopting packaging similar to NovaBay’s Avenova products, renowned as leading hypochlorous acid-based eye care items in the United States.
Under the terms of the agreement, Sonoma will remit a royalty fee to NovaBay based on the net sales of Ocudox by Avenova. Additionally, Sonoma will retain the right to continue marketing its Ocudox product within the European Union.
Sonoma CEO Amy Trombly said: “Sonoma has built a strong and growing presence in the European Union through a network of distributors and direct sales.
“We are excited to add Avenova-branded products to our offerings. At the same time, NovaBay has built strong brand recognition for Avenova in the dry eye market in the United States that we believe will resonate internationally.
“Ocudox sales in the European Union are already an important component of our business, and we see plenty of room to expand our eye care offerings.
“We are excited to partner with NovaBay on this opportunity, which we believe will allow more people to benefit from a quality hypochlorous acid product to aid in the treatment and symptoms of blepharitis on the eyelid.”
NovaBay CEO and general counsel Justin Hall said: “We are delighted that NovaBay will now be able to capitalise on sales of hypochlorous acid eye care products in the European Union.
“Sonoma’s CE mark includes a claim of treating blepharitis, the inflammation that typically affects the edges of the eyelids when tiny oil glands near the base of the eyelashes become clogged, causing irritation and redness. We’ve long asserted that blepharitis can lead to complications such as dry eye.
“The EU market is comparable in size to the US, giving NovaBay the opportunity to double its sales of Avenova. NovaBay will continue to be the exclusive seller of Avenova branded products in the US.”